| AntiagingAtlanta | |
Age Management Medicine News Letter - 07.11.06 Quality of Life is one of the primary goals of Age Management Medicine. Absence of the chronic diseases of aging is consistent with this goal. The inflammation process is implicated in the development of many diseases typically associated with aging such as heart disease, stroke, dementia, diabetes, and arthritis. C-Reactive Protein is a standard Age Management Medicine laboratory test used to measure inflammation in the body as well as the effects of treatment on inflammation levels. Inflammation levels can be lowered by optimizing hormone levels, utilizing certain dietary supplements such as omega 3 fatty acids, and making lifestyle modifications in the areas of diet and exercise. This article suggests that C-Reactive Protein levels are predictive of stroke risk in patients with cardiovascular disease: C-Reactive Protein Tied to Stroke Risk in Patients With Cardiovascular Disease: By David Douglas NEW YORK (Reuters Health) Jul 06 - Levels of C-reactive protein (CRP) correlate with ischemic stroke risk in patients with pre-existing cardiovascular disease, Israeli researchers report in the July issue of Stroke. Dr. David Tanne of Sheba Medical Center and Tel Aviv University and colleagues note that although CRP is an important predictor of cardiovascular disease, few prospective data are available on its association with ischemic stroke risk in such patients. The researchers examined this relationship in almost 3000 patients with stable coronary disease taking part in a clinical trial of bezafibrate, a fibric acid derivative. CRP levels were measured at baseline and about 2 years later. Over a mean follow-up of 6.2 years, the risk of ischemic stroke per 1000 patient-years increased from 4.1% in subjects with the lowest baseline levels of CRP (less than 2.3 mg/L) to 10.5% for those with the highest levels (more than 5.4 mg/L). After adjustment, those with the highest baseline CRP levels at baseline had a 2.16-fold increased hazard for stroke, compared to those with the lowest. At 2 years, the corresponding ratio was 2.43. Although bezafibrate reduced fibrinogen levels, it did not reduce CRP compared to placebo and there were no between-group differences in the risk of an incident ischemic stroke. "These findings," Dr. Tanne told Reuters Health, "show that we can better identify patients at high risk of stroke using this blood test (CRP), but whether one can prevent strokes by lowering the levels of this marker of inflammation, needs yet to be determined." |
Antiaging
Atlanta Phone:
770-842-1561 Call today today and speak with Dr. Smith to schedule your personal Age Management Medicine evaluation. To unsubscribe to our newsletter email Dr. Smith at: |